• Fortrea’s analysis points to intensifying competition in obesity drugs as next-generation therapies raise efficacy expectations.
• Retatrutide delivered mean weight reductions approaching 30% in some Phase III populations; publicly announced timelines suggest regulatory submissions may occur in 2027.
• High first-year treatment discontinuation makes long-term persistence a development priority, with tolerability, costs and reimbursement restrictions among key barriers.
• Future therapies will increasingly compete on sustained weight management, lean-mass preservation and broader health benefits rather than weight loss alone.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fortrea Holdings Inc. published the original content used to generate this news brief on November 01, 2026, and is solely responsible for the information contained therein.